Caution for psychiatrists: malignant hyperthermia risks with the anesthetic agent succinylcholine (Suxamethonium) during electroconvulsive therapy

Masaki Nakano,Michitaka Funayama,Taketo Takata,Riko Wakisaka,Genki Koyama,Akihiro Koreki,Takuto Ishida,Hiroyuki Uchida,Masaru Mimura
DOI: https://doi.org/10.1186/s12888-024-05846-5
IF: 4.144
2024-06-05
BMC Psychiatry
Abstract:Malignant hyperthermia is a potentially lethal condition triggered by specific anesthetic drugs, especially a depolarizing muscle relaxant of succinylcholine (Suxamethonium). Despite the frequent use of succinylcholine with electroconvulsive therapy (ECT), there has been no reported case of potentially lethal malignant hyperthermia following ECT. In addition, the time interval between the administration of succinylcholine and the onset of malignant hyperthermia has not been outlined in the context of ECT.
psychiatry
What problem does this paper attempt to address?